NCT00587587已完成1 期
A Prospective, Randomized, Controlled Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is Presented.
研究概览
简要总结
This pilot study will assess the safety and efficacy of Apligraf in the healing and recurrence of keloids post surgical shave excision in patients with clinically diagnosed keloids.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is between 18 and 65 years of age.
- •Subject or legal guardian has read, understood, and signed appropriate Institutional Review Board (IRB) approved informed consent, photography release form and HIPAA consent in their own language.
- •Subject with 1 keloid measuring between 1 cm2 - 40 cm2 as assessed by the Investigator, present for at least 6 months and a Beausang Scar scale combined score of 5 or greater.
- •Subject is a male or female who must have a documented negative urine pregnancy test if of child bearing potential. Sexually active females must be practicing a medically proven form of contraception during the course of the study period.
- •Subject and/or legal guardian must be able and willing to follow study procedures and instructions.
- •Subject and/or legal guardian must be able and willing to return for follow-up study visits.
- •Subject agrees to not use a keloid medication or injection treatment for four weeks prior to Day
- •Subject agrees not to use any other keloid treatments for the duration of the study.
- •Subject is otherwise healthy as assessed and determined by the Investigator
排除标准
- •Subject is suffering from a condition likely to require medical attention, including administration of any treatment which in the opinion of the Investigator could influence the results of the study.
- •Subject with any systemic condition like uncontrolled diabetes mellitus (glycosylated hemoglobin, HbA1C > 10%), cancer (biopsy confirming active malignancy), positive HIV test, or any disorder(s) that may compromise wound healing.
- •Subject is suffering from an abnormal skin condition on the affected area not usually associated with keloids such as psoriasis, or eczema.
- •Subject who is currently or has received topical or systemic steroid medication therapy within the past four weeks affecting the course of the keloid and/or its evaluability. Inhaled steroid therapy is acceptable.
- •Subject with the presence of acute infections in the areas intended for treatment.
- •Subject with known hypersensitivity to bovine collagen or to the components of the Apligraf agarose shipping medium.
- •Subject who is lactating or pregnant (positive result as determined by urine testing).
- •Subject with liver (ALT/SGPT, ALP, AST/SGOT, bilirubin, albumin, total protein, LDH) and/or renal function (BUN and creatinine) tests > 2 x upper limit of normal (ULN).
- •Subject who has been previously enrolled in any wound or investigational device study for any disease within the past four weeks.
- •Subject who has received an investigational drug or biological treatment within the past three months.
- •Subject previously treated with Apligraf, Dermagraft or any other cell therapy at the target keloid site.
- •Subject with a history of alcohol or substance abuse within the previous year, which could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes.
- •Subject with a history of anaphylaxis.
- •Subject who, in the opinion of the Investigator, for any reason other than those listed above, will not be able to complete the study per protocol
研究组 & 干预措施
A
Experimental
Apligraf (bilayered living cell therapy)
干预措施: Apligraf (Device)
B
Active Comparator
Dressing regimen comprised of a primary nonadherent dressing, dry gauze dressing and bolster gauze dressing, if necessary
干预措施: Standard dressing regimen (Other)
结局指标
主要结局
The Primary Purpose of This Study Will be to Gain Preliminary Safety Experience With Apligraf in the Keloid Indication. The Number of Participants Experiencing AEs is Presented.
时间窗: 52 weeks
Summary of all reported adverse events (AE) in the intent to treat (ITT) population. AE was defined as any adverse change in the subject's medical status compared with the subject's baseline condition, whether or not the event was related to the study device or a study procedure; or an exacerbation (either in frequency or severity) in a subject's pre-existing condition. AE data were collected at every study visit or if volunteered by the subject at any time during the study.
次要结局
- Change in Degree of Keloid Recurrence as Measured by Beausang Scar Scale (BSS)(Baseline to Week 52 or Last Visit)
- Degree of Recurrence (Scar Firmness)(Week 52 or Last Visit)
- Physician Global Assessment(Week 52 or Last Visit)
- Cumulative Incidence of Keloid Recurrence at Week 52(52 weeks)
- Degree of Recurrence (Scar Thickness)(Week 52 or Last visit)
- Decreased Utilization of Intralesional Steroid Intervention(52 weeks)
- Subject Global Assessment(Week 52 or Last Visit)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes MellitusOverweight and ObesityNCT06532578Guangzhou Chia Tai Innovative Pharmaceutical Co., Ltd.240
Unknown
不适用
Laser Therapy for Treatment of Genitourinary Syndrome of Menopause (GSM) in Postmenopausal WomenGenitourinary Syndrome of MenopauseNCT05305209University of Malaga189
已完成
不适用
A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ ProlapsedPelvic Organ ProlapseNCT02320643Samyang Biopharmaceuticals Corporation50
进行中（未招募）
3 期
Study of Efficacy of Different Treatment Regimens of OlokizumabCOVID-19NCT05187793R-Pharm198
已完成
不适用
Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot UlcersDiabetic Foot UlcerUlcer HealingNCT05797285ProgenaCare Global, LLC26